The Predictors for Continuous Renal Replacement Therapy in Liver Transplant Patient

Liver Transplantation Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01457534
• Other study ID #: 4-2010-0671
• Status: Completed
• Phase: N/A
• First received: October 4, 2011
• Last updated: February 26, 2013
• Start date: January 2011
• Est. completion date: February 2011

Study information

• Verified date: February 2013
• Source: Yonsei University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Background. Acute renal failure after liver transplantation (LT) requiring continuous renal replacement therapy (CRRT) adversely affects patient survival. However, there are few reports to assess the predictors for postoperative CRRT in liver transplant patients. The investigators undertook this study to identify perioperative factors that would predict patients at risk of CRRT.

Patients and Methods. The investigators retrospectively reviewed the data of 148 liver transplant patients from January 2007 to November 2010 at Severance Hospital, Yonsei University HealthSystem, in Seoul, Korea. The number of patients treated with CRRT was 44 (18 patients from living and 26 from deceased donors) and those without CRRT was 104. Univariate and stepwise logistic multivariate analyses were performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 148
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 19-65 year

• Liver transplant patients from January 2008 to December 2011

Exclusion Criteria:

• Patients treated with CRRT before transplantation

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Liver Transplantation

Locations

Country	Name	City	State
Korea, Republic of	Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (5)

Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation. 2001 May 27;71(10):1424-8. — View Citation

Holt AW, Bierer P, Bersten AD, Bury LK, Vedig AE. Continuous renal replacement therapy in critically ill patients: monitoring circuit function. Anaesth Intensive Care. 1996 Aug;24(4):423-9. — View Citation

Matsubara S, Okabe K, Ouchi K, Miyazaki Y, Yajima Y, Suzuki H, Otsuki M, Matsuno S. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure. Crit Care Med. 1990 Dec;18(12):1331-8. — View Citation

Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005 Jul;68(1):362-70. — View Citation

Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, Lin YF, Lu KC. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol. 2006 Jan;65(1):28-33. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	status before operation	laboratory data(ex : total bilirubin, albumin, coagulation factors, blood gas analysis(arterial CO2 pressure. Blood urea nitrate/Creatinine, Hemoglobin/Hematocrit.)	1 day before operation	No
Primary	the amount of ascites		intraoperative	No
Primary	the duration of anesthesia and operation		intraoperative	No
Primary	intraoperative hemodynamic instability		intraoperative	No
Primary	intraoperative bleeding		intraoperative	No
Primary	Intraoperative urine output		intraoperative	No
Primary	the types of donation(living or deceased donor)		intraoperative	No
Primary	survival rate		on the postoperative 28th days, 365 days	No
Primary	postoperative bleeding amount		on the postoperative 28th days, 365 days.	No
Primary	postoperative CRRT(continuous renal replacement therapy),		on the postoperative 28th days, 365days	No
Primary	mortality		on the postoperative 28th days, 365 days.	No